Anagram Therapeutics initiates Phase 2 trial for ANG003 in exocrine pancreatic insufficiency
Anagram Therapeutics is conducting Phase 2 study to evaluate the safety and efficacy of ANG003 for exocrine pancreatic insufficiency.
Company
Pharmaceutical intelligence for Anagram Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.